As per recent reports, it has been revealed that GlaxoSmithKline (GSK) has acquired Okairos AG for _250 million. By making such a move, the company has strengthened its vaccine business, said experts.

Experts continued by affirming that the recent acquisition of Okairos AG clearly shows that GSK wants to progress further in developing innovative medicines.

Recently, it has been revealed that Okairos AG has come up with a novel technology that will play a great role in the development of therapeutic and prophylactic vaccines. GSK's vaccine technology is said to perfectly blend with Okairos' technology and some new innovative vaccines are expected.

Christophe Weber, President of the GSK Vaccines, was of the view about the acquisition," is a fantastic opportunity for patients and our research organisation as it is expected to contribute to the development efforts for an exciting new generation of vaccines, building on the excellent science".

Weber continued by affirming that he is quite happy that acquisition deal has been done. They have done a lot of hard work and with the help of the acquisition; they will surely reach at the level where Okairos AG is present.

It is said that GSK will be taking the leadership as per the rules of the agreement done between the two companies.